

# Jennifer H Martin

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6517731/publications.pdf>

Version: 2024-02-01

242  
papers

7,743  
citations

66234

42  
h-index

64668

79  
g-index

248  
all docs

248  
docs citations

248  
times ranked

12038  
citing authors

#	ARTICLE	IF	CITATIONS
1	Reducing Inappropriate Polypharmacy. <i>JAMA Internal Medicine</i> , 2015, 175, 827.	2.6	1,054
2	Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis. <i>Breast Cancer Research and Treatment</i> , 2010, 123, 627-635.	1.1	785
3	Therapeutic drug monitoring of antimicrobials. <i>British Journal of Clinical Pharmacology</i> , 2012, 73, 27-36.	1.1	263
4	Resveratrol Does Not Benefit Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 2092-2103.e6.	2.4	237
5	Assessment of Nonischemic Myocardial Fibrosis. <i>Journal of the American College of Cardiology</i> , 2010, 56, 89-97.	1.2	219
6	Association of Liver Injury From Specific Drugs, or Groups of Drugs, With Polymorphisms in HLA and Other Genes in a Genome-Wide Association Study. <i>Gastroenterology</i> , 2017, 152, 1078-1089.	0.6	174
7	A randomised controlled trial of vaporised $\delta^9$ -tetrahydrocannabinol and cannabidiol alone and in combination in frequent and infrequent cannabis users: acute intoxication effects. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2019, 269, 17-35.	1.8	136
8	Endocytosis Inhibition in Humans to Improve Responses to ADCC-Mediating Antibodies. <i>Cell</i> , 2020, 180, 895-914.e27.	13.5	127
9	Association of Imaging Markers of Myocardial Fibrosis With Metabolic and Functional Disturbances in Early Diabetic Cardiomyopathy. <i>Circulation: Cardiovascular Imaging</i> , 2011, 4, 693-702.	1.3	122
10	The development and evaluation of an oncological palliative care deprescribing guideline: the $\text{\textcircled{OncPal}}$ deprescribing guideline $\text{\textcircled{TM}}$ . <i>Supportive Care in Cancer</i> , 2015, 23, 71-78.	1.0	112
11	Minimizing Inappropriate Medications in Older Populations: A 10-step Conceptual Framework. <i>American Journal of Medicine</i> , 2012, 125, 529-537.e4.	0.6	104
12	Tranilast attenuates cardiac matrix deposition in experimental diabetes: role of transforming growth factor- $\beta$ . <i>Cardiovascular Research</i> , 2005, 65, 694-701.	1.8	102
13	Marked increase in proton pump inhibitors use in Australia. <i>Pharmacoepidemiology and Drug Safety</i> , 2010, 19, 1019-1024.	0.9	101
14	Resveratrol $\text{\textcircled{“}}$ pills to replace a healthy diet?. <i>British Journal of Clinical Pharmacology</i> , 2011, 72, 27-38.	1.1	100
15	Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society Of Infectious Diseases Pharmacists. <i>Clinical Biochemist Reviews</i> , 2010, 31, 21-4.	3.3	98
16	A Missense Variant in PTPN22 is a Risk Factor for Drug-induced Liver Injury. <i>Gastroenterology</i> , 2019, 156, 1707-1716.e2.	0.6	97
17	Deciding when to stop: towards evidence-based deprescribing of drugs in older populations. <i>Evidence-Based Medicine</i> , 2013, 18, 121-124.	0.6	95
18	Therapeutic Effects of Prolonged Cannabidiol Treatment on Psychological Symptoms and Cognitive Function in Regular Cannabis Users: A Pragmatic Open-Label Clinical Trial. <i>Cannabis and Cannabinoid Research</i> , 2018, 3, 21-34.	1.5	93

#	ARTICLE	IF	CITATIONS
19	The role of the GP in follow-up cancer care: a systematic literature review. <i>Journal of Cancer Survivorship</i> , 2016, 10, 990-1011.	1.5	85
20	Cannabis contaminants: sources, distribution, human toxicity and pharmacologic effects. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 2468-2476.	1.1	85
21	Polypharmacy among inpatients aged 70 years or older in Australia. <i>Medical Journal of Australia</i> , 2015, 202, 373-377.	0.8	83
22	Using routine inpatient data to identify patients at risk of hospital readmission. <i>BMC Health Services Research</i> , 2009, 9, 96.	0.9	78
23	Functional, structural and molecular aspects of diastolic heart failure in the diabetic (mRen-2)27 rat. <i>Cardiovascular Research</i> , 2007, 76, 280-291.	1.8	72
24	Pitfalls of using estimations of glomerular filtration rate in an intensive care population. <i>Internal Medicine Journal</i> , 2011, 41, 537-543.	0.5	69
25	Diagnostic errors in older patients: a systematic review of incidence and potential causes in seven prevalent diseases. <i>International Journal of General Medicine</i> , 2016, 9, 137.	0.8	69
26	Can paracetamol (acetaminophen) be administered to patients with liver impairment?. <i>British Journal of Clinical Pharmacology</i> , 2016, 81, 210-222.	1.1	69
27	“LONG COVID” A hypothesis for understanding the biological basis and pharmacological treatment strategy. <i>Pharmacology Research and Perspectives</i> , 2022, 10, e00911.	1.1	69
28	Survival disparities in Australia: an analysis of patterns of care and comorbidities among indigenous and non-indigenous cancer patients. <i>BMC Cancer</i> , 2014, 14, 517.	1.1	66
29	Reducing potentially inappropriate medications in palliative cancer patients: evidence to support deprescribing approaches. <i>Supportive Care in Cancer</i> , 2014, 22, 1113-1119.	1.0	64
30	Systematic review: unmet supportive care needs in people diagnosed with chronic liver disease. <i>BMJ Open</i> , 2015, 5, e007451-e007451.	0.8	59
31	IN VITRO INHIBITORY EFFECTS OF ATORVASTATIN ON CARDIAC FIBROBLASTS: IMPLICATIONS FOR VENTRICULAR REMODELLING. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2005, 32, 697-701.	0.9	58
32	Pharmacokinetics in neonatal prescribing: evidence base, paradigms and the future. <i>British Journal of Clinical Pharmacology</i> , 2015, 80, 1281-1288.	1.1	58
33	Prolonged Cannabidiol Treatment Effects on Hippocampal Subfield Volumes in Current Cannabis Users. <i>Cannabis and Cannabinoid Research</i> , 2018, 3, 94-107.	1.5	58
34	Drug-Induced Liver Injury due to Flucloxacillin: Relevance of Multiple Human Leukocyte Antigen Alleles. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 245-253.	2.3	58
35	Incretin-based therapies – review of the physiology, pharmacology and emerging clinical experience. <i>Internal Medicine Journal</i> , 2011, 41, 299-307.	0.5	57
36	Tranilast attenuates diastolic dysfunction and structural injury in experimental diabetic cardiomyopathy. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2007, 293, H2860-H2869.	1.5	54

#	ARTICLE	IF	CITATIONS
37	Is cytochrome P450 2C9 genotype associated with NSAID gastric ulceration?. <i>British Journal of Clinical Pharmacology</i> , 2001, 51, 627-630.	1.1	49
38	Aiming to be NEAT: safely improving and sustaining access to emergency care in a tertiary referral hospital. <i>Australian Health Review</i> , 2014, 38, 564.	0.5	49
39	Cytochrome P450 Drug Interactions Within the HMG-CoA Reductase Inhibitor Class. <i>Drug Safety</i> , 2003, 26, 13-21.	1.4	48
40	Fibrosis as a Therapeutic Target Post-Myocardial Infarction. <i>Current Pharmaceutical Design</i> , 2005, 11, 477-487.	0.9	46
41	Quality of drug interaction alerts in prescribing and dispensing software. <i>Medical Journal of Australia</i> , 2009, 190, 251-254.	0.8	44
42	The effect of valproic acid in combination with irradiation and temozolomide on primary human glioblastoma cells. <i>Journal of Neuro-Oncology</i> , 2015, 122, 263-271.	1.4	44
43	Drug-associated pulmonary arterial hypertension. <i>Clinical Toxicology</i> , 2018, 56, 801-809.	0.8	43
44	Individualised medicine: why we need Bayesian dosing. <i>Internal Medicine Journal</i> , 2017, 47, 593-600.	0.5	40
45	Preoperative cisplatin, fluorouracil, and docetaxel with or without radiotherapy after poor early response to cisplatin and fluorouracil for resectable oesophageal adenocarcinoma (AGITG DOCTOR): results from a multicentre, randomised controlled phase II trial. <i>Annals of Oncology</i> , 2020, 31, 236-245.	0.6	39
46	Diagnostic sensitivity of carbohydrate deficient transferrin in heavy drinkers. <i>BMC Gastroenterology</i> , 2014, 14, 97.	0.8	37
47	Pharmacokinetics of Cannabis in Cancer Cachexia-Anorexia Syndrome. <i>Clinical Pharmacokinetics</i> , 2016, 55, 807-812.	1.6	36
48	Optimising low-dose methotrexate for rheumatoid arthritis – A review. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 2228-2234.	1.1	36
49	Current Status of Therapeutic Drug Monitoring in Australia and New Zealand: A Need for Improved Assay Evaluation, Best Practice Guidelines, and Professional Development. <i>Therapeutic Drug Monitoring</i> , 2010, 32, 615-623.	1.0	35
50	Using the apparent diffusion coefficient to identifying MGMT promoter methylation status early in glioblastoma: importance of analytical method. <i>Journal of Medical Radiation Sciences</i> , 2015, 62, 92-98.	0.8	35
51	Repurposing some older drugs that cross the blood-brain barrier and have potential anticancer activity to provide new treatment options for glioblastoma. <i>British Journal of Clinical Pharmacology</i> , 2016, 81, 199-209.	1.1	35
52	Defining and classifying terminology for medication harm: a call for consensus. <i>European Journal of Clinical Pharmacology</i> , 2019, 75, 137-145.	0.8	35
53	Therapeutic drug monitoring to adjust dosing in morbid obesity – a new use for an old methodology. <i>British Journal of Clinical Pharmacology</i> , 2012, 73, 685-690.	1.1	33
54	Medication-Related Problems in Outpatients With Decompensated Cirrhosis: Opportunities for Harm Prevention. <i>Hepatology Communications</i> , 2019, 3, 620-631.	2.0	33

#	ARTICLE	IF	CITATIONS
55	Effect of obesity on toxicity in women treated with adjuvant chemotherapy for early-stage breast cancer: a systematic review. <i>Breast Cancer Research and Treatment</i> , 2012, 136, 323-330.	1.1	32
56	When less is more – efficacy with less toxicity at the ED50. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 1365-1368.	1.1	32
57	Oral medicinal cannabinoids to relieve symptom burden in the palliative care of patients with advanced cancer: a double-blind, placebo controlled, randomised clinical trial of efficacy and safety of cannabidiol (CBD). <i>BMC Palliative Care</i> , 2019, 18, 110.	0.8	31
58	Exogenous Cannabinoid Efficacy: Merely a Pharmacokinetic Interaction?. <i>Clinical Pharmacokinetics</i> , 2018, 57, 539-545.	1.6	30
59	Clinical trials of medicinal cannabis for appetite-related symptoms from advanced cancer: a survey of preferences, attitudes and beliefs among patients willing to consider participation. <i>Internal Medicine Journal</i> , 2016, 46, 1269-1275.	0.5	29
60	Pharmacokinetic-Guided Dosing of New Oral Cancer Agents. <i>Journal of Clinical Pharmacology</i> , 2017, 57, S78-S98.	1.0	28
61	Comparative efficacy and safety of immunotherapies targeting the PD-1/PD-L1 pathway for previously treated advanced non-small cell lung cancer: A Bayesian network meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 142, 16-25.	2.0	28
62	Smoking and drug interactions. <i>Australian Prescriber</i> , 2013, 36, 102-104.	0.5	28
63	Toxicity and tolerability of adjuvant breast cancer chemotherapy in obese women. <i>Medical Oncology</i> , 2014, 31, 881.	1.2	27
64	Usefulness of At Rest and Exercise Hemodynamics to Detect Subclinical Myocardial Disease in Type 2 Diabetes Mellitus. <i>American Journal of Cardiology</i> , 2011, 107, 615-621.	0.7	26
65	Therapeutic drug monitoring in oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology consensus guidelines for imatinib therapy. <i>European Journal of Cancer</i> , 2021, 157, 428-440.	1.3	26
66	Postprandial total and HMW adiponectin following a high-fat meal in lean, obese and diabetic men. <i>European Journal of Clinical Nutrition</i> , 2013, 67, 377-384.	1.3	25
67	Prevalence of medication discrepancies in patients with cirrhosis: a pilot study. <i>BMC Gastroenterology</i> , 2016, 16, 114.	0.8	25
68	A Validated Method for the Detection of 32 Bath Salts in Oral Fluid. <i>Journal of Analytical Toxicology</i> , 2017, 41, 659-669.	1.7	25
69	Medication beliefs predict medication adherence in ambulatory patients with decompensated cirrhosis. <i>World Journal of Gastroenterology</i> , 2017, 23, 7321-7331.	1.4	25
70	The interacting physiology of COVID-19 and the renin-angiotensin-aldosterone system: Key agents for treatment. <i>Pharmacology Research and Perspectives</i> , 2022, 10, e00917.	1.1	25
71	Longitudinal Patterns of Breast Cancer Screening: Mammography, Clinical, and Breast Self-Examinations in a Rural and Urban Setting. <i>Women's Health Issues</i> , 2014, 24, e139-e146.	0.9	24
72	Follow-up cancer care: perspectives of Aboriginal and Torres Strait Islander cancer survivors. <i>Supportive Care in Cancer</i> , 2017, 25, 1597-1605.	1.0	24

#	ARTICLE	IF	CITATIONS
73	Statins and clinical outcomes in heart failure. <i>Clinical Science</i> , 2007, 113, 119-127.	1.8	23
74	Optimising care of patients with chronic disease: patient-oriented education may improve disease knowledge and self-management. <i>Internal Medicine Journal</i> , 2017, 47, 952-955.	0.5	23
75	Altered Sympathetic and Parasympathetic Activity in Lung Transplantation Patients at Rest and Following Autonomic Perturbation. <i>Chest</i> , 2002, 122, 1192-1199.	0.4	22
76	ROLE OF VALSARTAN AND OTHER ANGIOTENSIN RECEPTOR BLOCKING AGENTS IN THE MANAGEMENT OF CARDIOVASCULAR DISEASE. <i>Pharmacological Research</i> , 2002, 46, 203-212.	3.1	22
77	Gaps in predicting clinical doses for cannabinoids therapy: Overview of issues for pharmacokinetics and pharmacodynamics modelling. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 2483-2487.	1.1	22
78	Precision dosing of targeted anticancer drugs—challenges in the real world. <i>Translational Cancer Research</i> , 2017, 6, S1500-S1511.	0.4	22
79	eGFR use beyond the evidence. <i>Medical Journal of Australia</i> , 2009, 190, 197-199.	0.8	21
80	Reduced End-Systolic Pressure-Volume Ratio Response to Exercise. <i>Circulation: Cardiovascular Imaging</i> , 2010, 3, 443-449.	1.3	21
81	The Effect of a High-Fat Meal on Postprandial Arterial Stiffness in Men with Obesity and Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 4455-4459.	1.8	21
82	Impact of dose-rate on the low-dose hyper-radiosensitivity and induced radioresistance (HRS/IRR) response. <i>International Journal of Radiation Biology</i> , 2013, 89, 813-822.	1.0	21
83	Monte Carlo simulations of the clinical benefits from therapeutic drug monitoring of sunitinib in patients with gastrointestinal stromal tumours. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 78, 209-216.	1.1	21
84	Health-related quality of life among Indigenous Australians diagnosed with cancer. <i>Quality of Life Research</i> , 2016, 25, 1999-2008.	1.5	21
85	Exploratory study into the unmet supportive needs of people diagnosed with cirrhosis in Queensland, Australia. <i>Internal Medicine Journal</i> , 2017, 47, 429-435.	0.5	21
86	Oral medicinal cannabinoids to relieve symptom burden in the palliative care of patients with advanced cancer: a double-blind, placebo-controlled, randomised clinical trial of efficacy and safety of 1:1 delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD). <i>Trials</i> , 2020, 21, 611.	0.7	21
87	Reducing the burden of cancer for Aboriginal and Torres Strait Islander Australians: time for a coordinated, collaborative, priority-driven, Indigenous-led research program. <i>Medical Journal of Australia</i> , 2011, 194, 530-531.	0.8	20
88	Biomarker and imaging responses to spironolactone in subclinical diabetic cardiomyopathy. <i>European Heart Journal Cardiovascular Imaging</i> , 2014, 15, 776-786.	0.5	20
89	Systems analysis shows that thermodynamic physiological and pharmacological fundamentals drive COVID-19 and response to treatment. <i>Pharmacology Research and Perspectives</i> , 2022, 10, e00922.	1.1	20
90	Pill testing at music festivals: can we do more harm?. <i>Internal Medicine Journal</i> , 2016, 46, 1249-1251.	0.5	19

#	ARTICLE	IF	CITATIONS
91	A Validated Method for the Detection of Synthetic Cannabinoids in Oral Fluid. <i>Journal of Analytical Toxicology</i> , 2019, 43, 10-17.	1.7	19
92	Target Concentration Intervention in Oncology. <i>Therapeutic Drug Monitoring</i> , 2012, 34, 257-265.	1.0	18
93	The Effects of Tai Chi in Centrally Obese Adults with Depression Symptoms. <i>Evidence-based Complementary and Alternative Medicine</i> , 2015, 2015, 1-8.	0.5	18
94	Unraveling the complexity of therapeutic drug monitoring for monoclonal antibody therapies to individualize dose in oncology. <i>Pharmacology Research and Perspectives</i> , 2021, 9, e00757.	1.1	18
95	Factors Associated With Cancer-Specific and Overall Survival Among Indigenous and Non-Indigenous Gynecologic Cancer Patients in Queensland, Australia. <i>International Journal of Gynecological Cancer</i> , 2015, 25, 542-547.	1.2	17
96	Lessons learned from a pilot study of an Indigenous patient navigator intervention in Queensland, Australia. <i>European Journal of Cancer Care</i> , 2018, 27, e12714.	0.7	17
97	Spotlight Commentary: Model-informed precision dosing must demonstrate improved patient outcomes. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 2238-2240.	1.1	17
98	Translational hurdles with cannabis medicines. <i>Pharmacoepidemiology and Drug Safety</i> , 2020, 29, 1325-1330.	0.9	17
99	Repurposing existing therapeutics, its importance in oncology drug development: Kinases as a potential target. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 64-74.	1.1	17
100	Association of diabetes with survival among cohorts of Indigenous and non-Indigenous Australians with cancer. <i>Cancer Causes and Control</i> , 2009, 20, 355-360.	0.8	16
101	Medicinal cannabis in Australia: the missing links. <i>Medical Journal of Australia</i> , 2016, 204, 371-373.	0.8	16
102	Health professional's perspectives of the barriers and enablers to cancer care for Indigenous Australians. <i>European Journal of Cancer Care</i> , 2016, 25, 254-261.	0.7	16
103	Valproate in Adjuvant Glioblastoma Treatment. <i>Journal of Clinical Oncology</i> , 2016, 34, 3105-3107.	0.8	14
104	Breast cancer diagnosis, patterns of care and burden of disease in Queensland, Australia (1998-2004): does being Indigenous make a difference?. <i>International Journal of Public Health</i> , 2016, 61, 435-442.	1.0	14
105	Parasitic pharmacology: A plausible mechanism of action for cannabidiol. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 189-191.	1.1	14
106	Drug repurposing in the era of COVID-19: a call for leadership and government investment. <i>Medical Journal of Australia</i> , 2020, 212, 450.	0.8	14
107	Ensuring access to safe, effective, and affordable cannabis-based medicines. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 630-634.	1.1	14
108	Acidosis in the hospital setting: is metformin a common precipitant?. <i>Internal Medicine Journal</i> , 2010, 40, 342-346.	0.5	13

#	ARTICLE	IF	CITATIONS
109	The future of thiopurine pharmacogenomics. <i>Pharmacogenomics</i> , 2012, 13, 1549-1552.	0.6	13
110	Determination of a suitable voriconazole pharmacokinetic model for personalised dosing. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2016, 43, 165-177.	0.8	13
111	Achieving the World Health Organization's vision for clinical pharmacology. <i>British Journal of Clinical Pharmacology</i> , 2016, 81, 223-227.	1.1	13
112	Cytochrome P450 drug interactions: are they clinically relevant?. <i>Australian Prescriber</i> , 2001, 24, 10-12.	0.5	13
113	Medicines optimisation in older people: Taking age and sex into account. <i>Maturitas</i> , 2016, 93, 114-120.	1.0	12
114	Ezetimibe: Use, costs, and adverse events in Australia. <i>Cardiovascular Therapeutics</i> , 2017, 35, 40-46.	1.1	12
115	Patient-oriented education and medication management intervention for people with decompensated cirrhosis: study protocol for a randomized controlled trial. <i>Trials</i> , 2017, 18, 339.	0.7	12
116	Cannabinoid Disposition After Human Intraperitoneal Use: An Insight Into Intraperitoneal Pharmacokinetic Properties in Metastatic Cancer. <i>Clinical Therapeutics</i> , 2018, 40, 1442-1447.	1.1	12
117	The rationale of dose-response curves in selecting cancer drug dosing. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 2198-2204.	1.1	12
118	Khat-associated hepatitis. <i>Medical Journal of Australia</i> , 2013, 199, 498-499.	0.8	11
119	Addressing unconscious bias for female clinical academics. <i>Internal Medicine Journal</i> , 2016, 46, 391-393.	0.5	11
120	Model-based analysis on systemic availability of co-administered cannabinoids after controlled vaporised administration. <i>Internal Medicine Journal</i> , 2020, 50, 846-853.	0.5	11
121	Clinical trials with cannabis medicines" guidance for ethics committees, governance officers and researchers to streamline ethics applications and ensuring patient safety: considerations from the Australian experience. <i>Trials</i> , 2020, 21, 932.	0.7	11
122	Scanning for Safety. <i>CIN - Computers Informatics Nursing</i> , 2011, 29, 157-164.	0.3	11
123	Gender differences in doxorubicin pharmacology for subjects with chemosensitive cancers of young adulthood. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 82, 887-898.	1.1	10
124	Exploring Positive Survivorship Experiences of Indigenous Australian Cancer Patients. <i>International Journal of Environmental Research and Public Health</i> , 2018, 15, 135.	1.2	10
125	Effectiveness of patient-oriented education and medication management intervention in people with decompensated cirrhosis. <i>Internal Medicine Journal</i> , 2020, 50, 1142-1146.	0.5	10
126	Overcoming barriers to implementing precision dosing with 5-fluorouracil and capecitabine. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 317-325.	1.1	10



#	ARTICLE	IF	CITATIONS
127	Role of Statins in Diabetes Complications. <i>Current Diabetes Reviews</i> , 2009, 5, 165-170.	0.6	9
128	Evaluation of therapeutic enoxaparin in a pregnant population at a tertiary hospital. <i>Internal Medicine Journal</i> , 2016, 46, 826-833.	0.5	9
129	Identification of Australian Aboriginal and Torres Strait Islander Cancer Patients in the Primary Health Care Setting. <i>Frontiers in Public Health</i> , 2017, 5, 199.	1.3	9
130	Pharmacovigilance and expedited drug approvals. <i>Australian Prescriber</i> , 2018, 41, 50-53.	0.5	9
131	Community-identified recommendations to enhance cancer survivorship for Aboriginal and Torres Strait Islander people. <i>Australian Journal of Primary Health</i> , 2018, 24, 233.	0.4	9
132	Unmet supportive care needs among people with cancer: A cross-cultural comparison between Indigenous and Non-Indigenous Australians. <i>European Journal of Cancer Care</i> , 2019, 28, e13080.	0.7	9
133	Vancomycin therapeutic drug monitoring in paediatrics. <i>Journal of Paediatrics and Child Health</i> , 2020, 56, 563-570.	0.4	9
134	Barriers and Challenges in Performing Pharmacokinetic Studies to Inform Dosing in the Neonatal Population. <i>Pharmacy (Basel, Switzerland)</i> , 2020, 8, 16.	0.6	9
135	Communication, Collaboration and Care Coordination: The Three-Point Guide to Cancer Care Provision for Aboriginal and Torres Strait Islander Australians. <i>International Journal of Integrated Care</i> , 2020, 20, 10.	0.1	9
136	A systematic review and meta-analysis of toxicity and treatment outcomes with pharmacogenetic-guided dosing compared to standard of care BSA-based fluoropyrimidine dosing. <i>British Journal of Cancer</i> , 2022, 127, 126-136.	2.9	9
137	Stability of plasma creatinine concentrations in acute complex long-stay admissions to a general medical service. <i>Clinical Medicine</i> , 2010, 10, 540-543.	0.8	8
138	Surrogate endpoints in clinical practice: are we providing worse care?. <i>Internal Medicine Journal</i> , 2010, 40, 395-398.	0.5	8
139	Effects of a Drug Minimization Guide on Prescribing Intentions in Elderly Persons with Polypharmacy. <i>Drugs and Aging</i> , 2012, 29, 659-667.	1.3	8
140	A new frontier in haematology – combining pharmacokinetic with pharmacodynamic factors to improve choice and dose of drug. <i>British Journal of Clinical Pharmacology</i> , 2014, 78, 274-281.	1.1	8
141	Persistence of DNA adducts, hypermutation and acquisition of cellular resistance to alkylating agents in glioblastoma. <i>Cancer Biology and Therapy</i> , 2017, 18, 917-926.	1.5	8
142	“I’m a Survivor”. <i>Cancer Nursing</i> , 2020, 43, 105-114.	0.7	8
143	Vancomycin: Audit of American guideline-based intermittent dose administration with focus on overweight patients. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 958-965.	1.1	8
144	A pharmacological framework for integrating treating the host, drug repurposing and the damage response framework in COVID-19. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 875-885.	1.1	8

#	ARTICLE	IF	CITATIONS
145	The hazards of rapid approval of new drugs. <i>Australian Prescriber</i> , 2016, 39, 2-3.	0.5	8
146	Expert advice for prescribing cannabis medicines for patients with epilepsyâ€”drawn from the Australian clinical experience. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 3101-3113.	1.1	8
147	Effect of Atorvastatin on Cardiac Remodelling and Mortality in Rats Following Hyperglycemia and Myocardial Infarction. <i>International Journal of Cardiology</i> , 2010, 143, 353-360.	0.8	7
148	Ganciclovir pharmacokinetics and suggested dosing in continuous venovenous haemodiafiltration. <i>International Journal of Antimicrobial Agents</i> , 2011, 37, 90-92.	1.1	7
149	Fibronectin and transforming growth factor beta contribute to erythropoietin resistance and maladaptive cardiac hypertrophy. <i>Biochemical and Biophysical Research Communications</i> , 2014, 444, 332-337.	1.0	7
150	Second-Hand Exposure of Staff Administering Vaporised Cannabinoid Products to Patients in a Hospital Setting. <i>Drugs in R and D</i> , 2018, 18, 41-44.	1.1	7
151	Efficacy and toxicity of antihypertensive pharmacotherapy relative to effective dose 50. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 2218-2227.	1.1	7
152	Patterns of primary health care service use of Indigenous Australians diagnosed with cancer. <i>Supportive Care in Cancer</i> , 2020, 28, 317-327.	1.0	7
153	Buying time: Drug repurposing to treat the host in COVIDâ€”19H. <i>Pharmacology Research and Perspectives</i> , 2020, 8, e00620.	1.1	7
154	Editorial: Reporting adverse drug events to the Therapeutic Goods Administration. <i>Australian Prescriber</i> , 2021, 44, 2-3.	0.5	7
155	Pharmacokinetics, Safety, and Tolerability of a Medicinal Cannabis Formulation in Patients with Chronic Non-cancer Pain on Long-Term High Dose Opioid Analgesia: A Pilot Study. <i>Pain and Therapy</i> , 2022, 11, 171-189.	1.5	7
156	Drug Development. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2012, 55, 506-510.	0.9	6
157	<scp>BMI</scp> But Not Stage or Etiology of Nonalcoholic Liver Disease Affects the Diagnostic Utility of Carbohydrateâ€”Deficient Transferrin. <i>Alcoholism: Clinical and Experimental Research</i> , 2013, 37, 1771-1778.	1.4	6
158	Ruralâ€”urban disparities in stage of breast cancer at diagnosis in <scp>A</scp>ustralian women. <i>Australian Journal of Rural Health</i> , 2016, 24, 326-332.	0.7	6
159	Safety and efficacy of statins. <i>Lancet, The</i> , 2017, 389, 1098.	6.3	6
160	Compassion and evidence in prescribing cannabinoids: a perspective from the Royal Australasian College of Physicians. <i>Medical Journal of Australia</i> , 2018, 208, 107-109.	0.8	6
161	Systematic review of interventions to improve safety and quality of anticoagulant prescribing for therapeutic indications for hospital inpatients. <i>European Journal of Clinical Pharmacology</i> , 2019, 75, 1645-1657.	0.8	6
162	Precision medicineâ€”based drug treatment individualization in oncology. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 223-226.	1.1	6

#	ARTICLE	IF	CITATIONS
163	Measurement of 5- fluorouracil, capecitabine and its metabolite concentrations in blood using volumetric absorptive microsampling technology and LC-MS/MS. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2022, 1188, 123075.	1.2	6
164	Timing of Live Attenuated Vaccination in Infants Exposed to Infliximab or Adalimumab <i>in Utero</i> : A Prospective Cohort Study in 107 Children. Journal of Crohn's and Colitis, 2022, 16, 1835-1844.	0.6	6
165	Mortality from common drug interactions systems, knowledge and clinical reasoning to optimise prescribing. Internal Medicine Journal, 2014, 44, 621-624.	0.5	5
166	Adding the "medicines" back into personalized medicine to improve cancer treatment outcomes. British Journal of Clinical Pharmacology, 2015, 80, 929-931.	1.1	5
167	Where is the radiobiology and pharmacology research to improve outcomes in glioblastoma?. Journal of Neuro-Oncology, 2015, 124, 1-3.	1.4	5
168	Clinical Consequences of a Miscalibrated Digoxin Immunoassay. Therapeutic Drug Monitoring, 2015, 37, 104-109.	1.0	5
169	The Impact of Model-Misspecification on Model Based Personalised Dosing. AAPS Journal, 2016, 18, 1244-1253.	2.2	5
170	Care and concern with cannabinoids used therapeutically. British Journal of Clinical Pharmacology, 2018, 84, 2455-2457.	1.1	5
171	NSW Cannabis Medicines Advisory Service preliminary survey results: enquirer perceptions and patient outcomes. Internal Medicine Journal, 2022, 52, 228-237.	0.5	5
172	How reliable is eGFR when calculating drug dosage in acute medical admissions?. Internal Medicine Journal, 2011, 41, 327-331.	0.5	4
173	Enabling the success of academic health science centres in Australia: where is the leadership?. Medical Journal of Australia, 2014, 201, 636-638.	0.8	4
174	How "Optimal" are Optimal Sampling Times for Tyrosine Kinase Inhibitors in Cancer? Practical Considerations. Clinical Pharmacokinetics, 2016, 55, 1171-1177.	1.6	4
175	Obesity and COVID-19: renin-angiotensin as a mediator of morbidity and mortality. British Journal of Nutrition, 2022, 127, 1439-1440.	1.2	4
176	New medicines "urgent need to assess outcomes in special groups. Medical Journal of Australia, 2012, 196, 433-433.	0.8	3
177	Diamantina Health Partners: integrating leadership in research, research translation, education and clinical care. Medical Journal of Australia, 2012, 196, 237-239.	0.8	3
178	Policy change to improve pathology turnaround time and reduce costs "possible to do both?. Biochemia Medica, 2013, 23, 296-302.	1.2	3
179	Clinical research in synthetic cannabinoids "do we need a national approach?. Medical Journal of Australia, 2014, 201, 317-319.	0.8	3
180	New imaging techniques for more effective treatment in glioblastoma. Internal Medicine Journal, 2014, 44, 5-6.	0.5	3

#	ARTICLE	IF	CITATIONS
181	Improving ambulatory patient-centred practice with a patient teaching associate programme. <i>Internal Medicine Journal</i> , 2015, 45, 883-884.	0.5	3
182	Lipid and other management to improve arterial disease and survival in end stage renal disease. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 343-349.	0.9	3
183	Clinical benefits of evolocumab appear less than hoped. <i>Lancet, The</i> , 2018, 391, 933-934.	6.3	3
184	Weight-based tacrolimus trough concentrations post liver transplant. <i>Internal Medicine Journal</i> , 2019, 49, 79-83.	0.5	3
185	DRUG REPURPOSING—Overcoming the translational hurdles to clinical use. <i>Pharmacology Research and Perspectives</i> , 2019, 7, e00548.	1.1	3
186	Using Therapeutic Drug Monitoring and Pharmacovigilance to Overcome Some of the Challenges of Developing Medicinal Cannabis from Botanical Origins. <i>Therapeutic Drug Monitoring</i> , 2020, 42, 98-101.	1.0	3
187	Inability of Current Dosing to Achieve Carboplatin Therapeutic Targets in People with Advanced Non-Small Cell Lung Cancer: Impact of Systemic Inflammation on Carboplatin Exposure and Clinical Outcomes. <i>Clinical Pharmacokinetics</i> , 2020, 59, 1013-1026.	1.6	3
188	Aboriginal and Torres Strait Islander patients' cancer care pathways in Queensland: Insights from health professionals. <i>Health Promotion Journal of Australia</i> , 2022, 33, 701-710.	0.6	3
189	Severe hyperkalaemia with prescription of potassium-retaining agents in an elderly patient. <i>New Zealand Medical Journal</i> , 2003, 116, U542.	0.5	3
190	Guidelines or external regulation?. <i>Internal Medicine Journal</i> , 2009, 39, 789-791.	0.5	2
191	Old bugs new populations: an unusual presentation of pericarditis. <i>Internal Medicine Journal</i> , 2009, 39, 850-851.	0.5	2
192	From an evolutionary perspective, all "new" antimicrobial targets are old: time to think outside the box. <i>British Journal of Clinical Pharmacology</i> , 2015, 79, 165-167.	1.1	2
193	Off-label use of tumour necrosis factor- $\alpha$ inhibitors and anakinra at an Australian tertiary hospital. <i>Internal Medicine Journal</i> , 2016, 46, 1386-1391.	0.5	2
194	Predicting drug interactions in addiction treatment. <i>Internal Medicine Journal</i> , 2017, 47, 872-878.	0.5	2
195	Laxative Use in Inpatients on Oxycodone/Naloxone Prolonged Release and Oxycodone Prolonged Release for Cancer and Non-cancer Pain. <i>Journal of Pain and Palliative Care Pharmacotherapy</i> , 2018, 32, 116-123.	0.5	2
196	Optimal cancer drug dosing in adolescents: new issues and the old unaddressed ones. <i>Internal Medicine Journal</i> , 2018, 48, 1023-1027.	0.5	2
197	Intensive lipid-lowering therapy in the 12 months after an acute coronary syndrome in Australia: an observational analysis. <i>Medical Journal of Australia</i> , 2019, 211, 284.	0.8	2
198	Did our pharmacological strategy for COVID-19 fail?. <i>Pharmacology Research and Perspectives</i> , 2021, 9, e00866.	1.1	2

#	ARTICLE	IF	CITATIONS
199	The HEART FAILURE Journal Club: a review of publications on heart failure in American Heart Journal. European Journal of Heart Failure, 2001, 3, 125-137.	2.9	1
200	Novel Drug Treatments for Hypertension. , 2007, , 1049-1060.		1
201	Statins and congestive heart failure. Current Atherosclerosis Reports, 2008, 10, 369-376.	2.0	1
202	Whither therapeutic drug monitoring?. Internal Medicine Journal, 2010, 40, 671-672.	0.5	1
203	Treatment for pulmonary hypertension in Australia: too far too fast?. Internal Medicine Journal, 2011, 41, 217-219.	0.5	1
204	Challenges of an ageing and dispersed population for delivering cancer services in Australia: more than just doctors needed. Internal Medicine Journal, 2012, 42, 349-351.	0.5	1
205	A Simple and Sensitive LC-MS/MS Method for the Simultaneous Determination of Cyclophosphamide and Doxorubicin Concentrations in Human Plasma. Current Pharmaceutical Analysis, 2017, 14, .	0.3	1
206	The challenge of discharge: combining medication reconciliation and discharge planning. Medical Journal of Australia, 2017, 206, 20-21.	0.8	1
207	Use of complementary and alternative medicines in people with depression and central obesity: Findings from a Tai Chi and Qigong study. Journal of Traditional Chinese Medical Sciences, 2018, 5, 100-109.	0.1	1
208	Letter to the Editor: Automated adverse drug reaction detection. Australian Prescriber, 2018, 41, 138.	0.5	1
209	Cannabinoid use in practice in Australasiaâ€”Better guidance and new drug information systems will be essential for prescribers. British Journal of Clinical Pharmacology, 2019, 85, 1664-1665.	1.1	1
210	Development of an UHPLC-MS/MS method for remifentanyl quantification in a small plasma volume. Journal of Liquid Chromatography and Related Technologies, 2019, 42, 521-527.	0.5	1
211	Taking the brake off the immune system: Hypotheses, trials, tribulations, and the evolving discipline of clinical immunopharmacology. British Journal of Clinical Pharmacology, 2020, 86, 1674-1677.	1.1	1
212	Effect of pharmaceutical regulatory policy on health impact. British Journal of Clinical Pharmacology, 2020, 86, 2335-2337.	1.1	1
213	College conferences: time for meritâ€”based selection of speakers and educators?. Internal Medicine Journal, 2020, 50, 393-395.	0.5	1
214	Evaluation of pharmacogenomics and hepatic nuclear imagingâ€”related covariates by population pharmacokinetic models of irinotecan and its metabolites. European Journal of Clinical Pharmacology, 2021, , 1.	0.8	1
215	The Development of a Rapid, Simple and Sensitive LC-MS/MS Method, to Guide Clinical Dosing, for the Analysis of 5-Fluorouracil in Human Plasma. Current Pharmaceutical Analysis, 2017, 13, .	0.3	1
216	Editorial: The challenge of costly drugs. Australian Prescriber, 2016, 39, 72-4.	0.5	1

#	ARTICLE	IF	CITATIONS
217	On strongly unimodal third-order SISO linear systems with applications to pharmacokinetics. IFAC-PapersOnLine, 2020, 53, 4654-4661.	0.5	1
218	Medication Discrepancies and Regimen Complexity in Decompensated Cirrhosis: Implications for Medication Safety. Pharmaceuticals, 2021, 14, 1207.	1.7	1
219	Patient-oriented medication education intervention has long-term benefits for people with decompensated cirrhosis. Hepatology Communications, 2022, 6, 3281-3282.	2.0	1
220	Doctors and the pharmaceutical industry: time for a national policy?. Medical Journal of Australia, 2009, 191, 189-190.	0.8	0
221	Rapidly Progressive Severe Amiodarone-Induced Hypothyroidism in an Elderly Female. Journal of Pharmacy Practice and Research, 2009, 39, 140-141.	0.5	0
222	Drug Use Evaluation Services in Australia and New Zealand: a Neglected Area of Research?. Journal of Pharmacy Practice and Research, 2010, 40, 15-18.	0.5	0
223	ORIGINAL ARTICLE: Comparison of a Commonwealth-initiated regional radiation oncology facility in Toowoomba with a Queensland Health facility. Journal of Medical Imaging and Radiation Oncology, 2010, 54, 368-374.	0.9	0
224	Pharmacogenomics and Warfarin Therapy. , 2012, , 161-173.		0
225	Issues of Pharmacogenomics in Monitoring Warfarin Therapy. , 2016, , 261-277.		0
226	Medicinal cannabis in Australia: the missing links. Medical Journal of Australia, 2016, 205, 425-425.	0.8	0
227	Trading Lower HbA 1c for Increased Adverse Events. Journal of the American College of Cardiology, 2016, 68, 1372-1373.	1.2	0
228	Care with overseas purchased drugs: devil is in the detail. Internal Medicine Journal, 2016, 46, 1005-1006.	0.5	0
229	Introduction. Internal Medicine Journal, 2017, 47, 157-158.	0.5	0
230	Comment on a paper by Dupoiron et al. A phase III randomized controlled study on the efficacy and improved bowel function of prolonged-release oxycodone-naloxone (up) Tj ETQq 0 0 rg BT/Overlock	0.4	0
231	Selected state of the art research in internal medicine, 2017. Internal Medicine Journal, 2018, 48, 619-623.	0.5	0
232	Reply. Hepatology Communications, 2019, 3, 1283-1284.	2.0	0
233	Clinically Optimal Versus Target Doses in Heart Failure. Journal of the American College of Cardiology, 2019, 74, 1425.	1.2	0
234	Are general practitioners getting the information they need from hospitals and specialists to provide quality cancer care for Indigenous Australians?. Internal Medicine Journal, 2020, 50, 38-47.	0.5	0

#	ARTICLE	IF	CITATIONS
235	Science and art of anticancer drug dosing: nine steps to personalised therapy. <i>Internal Medicine Journal</i> , 2020, 50, 992-996.	0.5	0
236	Andrew Lawrence, Editor-in-Chief 2018-2020. <i>Pharmacology Research and Perspectives</i> , 2020, 8, e00702.	1.1	0
237	Easier patient access to medical cannabis carries risks as well as benefits. <i>Journal of Psychopharmacology</i> , 2021, 35, 1435-1436.	2.0	0
238	<i>Pharmacology Research &amp; Perspectives</i> calls for pharmacology education papers. <i>Pharmacology Research and Perspectives</i> , 2021, 9, e00772.	1.1	0
239	Letter: The challenge of costly drugs. <i>Australian Prescriber</i> , 2016, 39, 149-149.	0.5	0
240	Defining the trials nurses'™ role in operationalising a medicinal cannabis clinical trial. <i>Collegian</i> , 2021, , .	0.6	0
241	Critical insights to COVID-19 disease and potential treatments using a systems analysis approach that integrates physiology, pharmacology, and clinical pharmacology. <i>Pharmacology Research and Perspectives</i> , 2022, 10, e00918.	1.1	0
242	Melanoma: An immunotherapy journey from bench to bedside. <i>Cancer Treatment and Research</i> , 2022, 183, 49-89.	0.2	0